These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 26673798)
1. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133 [TBL] [Abstract][Full Text] [Related]
3. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820 [TBL] [Abstract][Full Text] [Related]
5. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study. Bashir A; Brennum J; Broholm H; Law I J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154 [TBL] [Abstract][Full Text] [Related]
6. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699 [TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET. Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552 [TBL] [Abstract][Full Text] [Related]
9. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298 [TBL] [Abstract][Full Text] [Related]
14. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067 [TBL] [Abstract][Full Text] [Related]
15. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742 [TBL] [Abstract][Full Text] [Related]
17. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325 [TBL] [Abstract][Full Text] [Related]
18. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense? Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893 [TBL] [Abstract][Full Text] [Related]
20. Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis. Panholzer J; Malsiner-Walli G; Grün B; Kalev O; Sonnberger M; Pichler R Clin Neuroradiol; 2024 Jun; 34(2):351-360. PubMed ID: 38157019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]